06 May 2019 | News
The PhysioMimix Organ-on-Chip platform enables researchers to work with a wide range of cell types
image credit- shuttershock.com
Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s supplier of high technology scientific equipment. The agreement will see AXT distribute CN Bio’s innovative bioengineering products to medical researchers in academia and industry throughout Australia, New Zealand and the South Pacific region.
CN Bio is lab-on-a-chip company, based in London. It’s flagship PhysioMimix device is being used by pharmaceutical, consumer goods companies and regulators globally.
Paul Davies, CN Bio Commercial Director Paul Davies said, “PhysioMimix allows researchers to run single- and multi-organ human-tissue based studies, in parallel, on a compact lab-benchtop device. For teams who need human-relevant data as part of their research, preclinical testing, and to assess the safety or toxicity of new compounds, Organ-on-Chip studies are becoming absolutely invaluable. They provide comprehensive, 3D tissue-culture-based data and enable real-time monitoring and analysis.”
“AXT provide equipment to many of these teams already. A lot of groups in Australia and New Zealand are looking forward to adding the latest Organ-on-Chip techniques to their labs, and we’re delighted that they will have friendly faces to demonstrate and set up the CN Bio devices.”
Richard Trett, Managing Director of AXT said, “We are excited to bring CN Bio on board. Their addition to our existing portfolio continues our commitment to put the latest technologies in the hands of Australian researchers.”
The PhysioMimix Organ-on-Chip platform enables researchers to work with a wide range of cell types (iPSCs, primary cells, etc.) and commercial inserts to mimic human physiology in vitro.
This improves the efficiency of preclinical studies or industrial screening that require reliable human-relevant data.